GlassScriptPhysician profile
Amit V Vora
NPI 1295999142
$1,117.08
in general payments reported to CMS, 2019-2025
17 companies · $237 in 2025
The $237 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.48 · 2022: $308 · 2023: $205 · 2024: $340 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $781.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $297.19 | 2022-2025 | Clareon, Tryptyr, Rocklatan |
| Medtronic, INC. | $224.10 | 2022-2024 | Corevalve Evolut R |
| Abbvie INC. | $192.91 | 2023-2025 | |
| Astellas Pharma US INC | $65.89 | 2023-2025 | Izervay |
| Oyster Point Pharma, INC. | $45.16 | 2022-2024 | Tyrvaya |
| Horizon Therapeutics Plc | $42.09 | 2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $35.55 | 2025 | |
| Amgen INC. | $34.74 | 2024 | Tepezza |
| Mallinckrodt Hospital Products INC. | $30.57 | 2022-2023 | Acthar |
| Bausch & Lomb Americas INC. | $29.80 | 2022 | |
| Coopervision INC. | $19.16 | 2022 | |
| Dompe US, INC. | $19.00 | 2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $18.99 | 2025 | Xdemvy |
| Genmab U.S., INC. | $18.81 | 2023 | Tivdak |
| Ocular Therapeutix, INC. | $15.64 | 2023 | Dextenza |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.79 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Vora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.